Compare Stocks → The Hidden Anchor Investment of the Elite Revealed (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:RZLT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRZLTRezolute$4.17+3.5%$2.89$0.72▼$4.40$167.34M1.3444,686 shs401,156 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRZLTRezolute0.00%+13.20%+21.75%+109.90%+95.63%The Hidden Anchor Investment of the Elite Revealed (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRZLTRezolute3.6013 of 5 stars3.54.00.00.04.05.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRZLTRezolute3.00Buy$8.80111.03% UpsideCurrent Analyst RatingsLatest ARIX and RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.005/16/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.004/18/2024RZLTRezoluteJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.004/18/2024RZLTRezoluteJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/9/2024RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.003/7/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00(Data available from 6/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRZLTRezoluteN/AN/AN/AN/A$3.15 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRZLTRezolute-$51.79M-$1.14N/AN/AN/AN/A-60.90%-54.58%9/12/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRZLTRezoluteN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRZLTRezoluteN/A11.8211.82OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipRZLTRezolute20.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableRZLTRezolute5740.13 million31.79 millionNot OptionableARIX and RZLT HeadlinesRecent News About These CompaniesMay 30, 2024 | globenewswire.comRezolute to Participate in the Jefferies Global Healthcare ConferenceMay 30, 2024 | americanbankingnews.comBrian Kenneth Roberts Purchases 7,500 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockMay 29, 2024 | insidertrades.comRezolute, Inc. (NASDAQ:RZLT) Insider Brian Kenneth Roberts Buys 7,500 SharesMay 28, 2024 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Insider Purchases $20,175.00 in StockMay 22, 2024 | finanznachrichten.deRezolute, Inc.: Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)May 22, 2024 | msn.comWhy Is Small-Cap Metabolic-Focused Rezolute Stock Trading Higher On Wednesday?May 22, 2024 | markets.businessinsider.comRezolute’s RZ402 Shows Promising Efficacy and Safety in DME Treatment, Reinforcing Buy RatingMay 22, 2024 | marketbeat.comRezolute (NASDAQ:RZLT) Rating Reiterated by HC WainwrightMay 21, 2024 | globenewswire.comRezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)May 17, 2024 | markets.businessinsider.comBuy Rating on Rezolute: Unrecognized Potential in DME Treatment and Advancements in RZ358 for HyperinsulinismMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed on Rezolute’s Solid Financials and Advancing Clinical TrialsMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rezolute Amidst Clinical Progress and Market OpportunityMay 16, 2024 | finanznachrichten.deRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business UpdateMay 16, 2024 | marketbeat.comRezolute's (RZLT) "Buy" Rating Reiterated at HC WainwrightMay 16, 2024 | investorplace.comRZLT Stock Earnings: Rezolute Misses EPS for Q3 2024May 15, 2024 | globenewswire.comRezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business UpdateMay 12, 2024 | nasdaq.comRezolute, Inc. Common Stock (NV) (RZLT) NewsMay 10, 2024 | finance.yahoo.comRezolute, Inc. (NASDAQ:RZLT) has caught the attention of institutional investors who hold a sizeable 47% stakeMay 9, 2024 | marketbeat.comVivo Capital LLC Raises Position in Rezolute, Inc. (NASDAQ:RZLT)April 23, 2024 | globenewswire.comPhase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual MeetingApril 19, 2024 | msn.comJonesTrading Initiates Coverage of Rezolute (RZLT) with Buy RecommendationNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsRezoluteNASDAQ:RZLTRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
